| 2.91 -0.065 (-2.18%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.34 | 1-year : | 6.68 |
| Resists | First : | 4.57 | Second : | 5.72 |
| Pivot price | 3.21 |
|||
| Supports | First : | 2.71 | Second : | 2.25 |
| MAs | MA(5) : | 2.88 |
MA(20) : | 3.46 |
| MA(100) : | 4.5 |
MA(250) : | 6.34 |
|
| MACD | MACD : | -0.5  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 13.7 |
D(3) : | 11.5 |
| RSI | RSI(14): 35.7 |
|||
| 52-week | High : | 10.97 | Low : | 2.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ADVM ] has closed above bottom band by 26.6%. Bollinger Bands are 3.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.01 - 3.02 | 3.02 - 3.03 |
| Low: | 2.77 - 2.79 | 2.79 - 2.8 |
| Close: | 2.88 - 2.91 | 2.91 - 2.94 |
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Fri, 25 Apr 2025
Press Release Distribution & PR Platform - ACCESS Newswire
Wed, 23 Apr 2025
Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Wed, 23 Apr 2025
Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX
Tue, 22 Apr 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM - PR Newswire
Sun, 20 Apr 2025
Chardan Capital Cuts Adverum Biotechnologies (NASDAQ:ADVM) Price Target to $33.00 - American Banking and Market News
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 1.253e+007 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 1,400 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.902e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 922 % |
| Return on Equity (ttm) | -29.9 % |
| Qtrly Rev. Growth | 1e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -69.97 |
| EBITDA (p.s.) | -6.16697e+007 |
| Qtrly Earnings Growth | -6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -86 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 0.45 |
| Dividend | 0 |
| Forward Dividend | 1.48e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|